Filter by: patients
Home > Community Treatment Reports and Side Effects > Agomelatine Treatment Report
What is Agomelatine?

Agomelatine, (trade names Valdoxan, Melitor, Thymanax) is a melatonergic antidepressant not currently available in the US. Due to its unique profile it has not been associated with weight gain, sexual side effects, or withdrawal syndrome as experienced with other antidepressants.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Major Depressive Disorder 3 0
Anxious mood 2 0
Treat my mood condition(s) 2 1 Efficacy_none
Difficulty sleeping through night 1 1 Efficacy_major
Dysthymia 1 1 Efficacy_slight

See all 5 patients currently taking Agomelatine

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 0
None
 3

Reported Dosages

  25 mg daily 50 mg daily
  3 Number of Patients: 3 2 Number of Patients: 2  

Reported Stop Reasons

Why Patients Stopped Taking Agomelatine (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 1   Did not seem to work: 100%

See all 1 patient who’ve stopped taking Agomelatine

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Agomelatine

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Stopped Taking Agomelatine

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Agomelatine

Always
 3 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Agomelatine

Very
 0 0%
Somewhat
 0 0%
A little
 0 0%
Not at all
 3 100%

Cost

Paid out of pocket

Cost of Agomelatine

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 1 100%

Report created on May 28, 2012.